Skip to Main Content

Biogen said Thursday it will pay more than $1 billion to the biotech firm Denali for rights to a Parkinson’s drug based on an approach that was nearly abandoned by several major pharmaceutical firms in recent years but that has since shown potential to help treat the disease. The deal also includes rights to a Denali technology for delivering medicines to the brain.

“This is a major milestone,” said Ryan Watts, Denali’s CEO and co-founder. He said the company had “the firepower to do very thorough science and drug development,” which meant that it also had the wherewithal to previously move beyond the failure of other promising programs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Matt,

    I was expecting you to mention and also cover in more detail DNL 747 and it’s backup compound DNL 788 but obviously, you decided no to. Why?

Comments are closed.